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A 59-year old male had odynophagia and globus sensation for 10 days prior to his visit. Endoscopically, a fungating
mass was observed in the right side of the tongue base (BOT). The peripheral T-cell lymphoma (PTCL) was confirmed
by a punch biopsy. The patient was classified as stage IIA according to the Ann Arbor staging classification. Radiation
therapy (RT) using volumetric modulated arc therapy (VAMT) began after 8 cycles of CHOP chemotherapy. Although
the patient achieved a complete remission without RT relating morbidity during the follow-up period, recurrence
occurred in the right orbit at 3 months after treatment. The patient received RT with high energy electron on
the right orbit. The salvage chemotherapy was followed by RT. The patient died of aggravation of PTCL at
17 months after VMAT. We report a poor prognostic case of PTCL in BOT with chemotherapy followed by RT.
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The incidence of Non-Hodgkin’s lymphoma (NHL) of
the oral cavity accounts for 3-5% of all malignant lesions
of the oral cavity. Further, only 1% of all lymphomas are
primary oral cavity lymphoma. NHL in the base of
tongue (BOT) is even rarer (Lee et al. 1987); (Zapater
et al. 2010). Primary oral cavity lymphoma occurs in
Waldeyer`s ring, including the tonsils, nasopharyngeal
lymphoid tissue, soft palate, and BOT (Lee et al. 2014).
Diffuse large B cell lymphoma (DLBCL) has been re-
ported as the most common type of primary oral NHL
(Kemp et al. 2008). However, the Peripheral T-cell lymph-
omas (PTCL) in the head and neck (H&N) region were
rarely reported (Jaffe 2002). Because of its rarity, the treat-
ment guidelines for primary BOT lymphoma have not
been clearly established (Guastafierro et al. 2008). Gener-
ally, the standard treatment for patients with early stage
DLBCL is chemotherapy followed by involved field ra-
diation therapy (IFRT) (You et al. 2004). Among H&N
lymphoma cases treated with IFRT followed by chemother-
apy, most were traditionally treated with three dimensional* Correspondence: souko@gilhospital.com
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It has been well known that 3D-CRT in H&N cancer pa-
tients could increase the incidence of xerostomia, whereas
the volumetric modulated arc therapy (VMAT) could
significantly reduce the incidence of RT-induced toxicity
(Holt et al. 2013). We here report a poor prognostic case
of PTCL in BOT with chemotherapy followed by RT with
the use of VMAT.Case description
A 59-year old male had odynophagia and globus sensa-
tion for 10 days before his visit. A fungating mass was
observed endoscopically on the right side of the tongue
base. The tumor mass originated from the base of the
tongue and extended to the right pyriform sinus. The
tumor measured approximately 3 cm longitudinally and
2.7 cm transversally. The patient experienced no B symp-
toms (fever, weight loss, and night sweats). The Eastern
Cooperative Oncology Group (ECOG) performance status
of the patient was 0–1. The laboratory results at the
time of admission were as follows: lactate dehydrogenase
(LDH), 380 U/l) (normal range, 120–520); white cell
count, 6,040/μl (normal range, 4,000-10,000); hemoglobin,
14.0 g/dl (normal range, 13–17); platelet count, 289,000/μl
(normal range, 150–450); aspirate aminotransferase,n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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21 IU/l (normal range, 5–40); blood urea nitrogen,
16.7 mg/dl (normal range, 8–22); and creatinine, 0.7 mg/dl
(normal range, 0.6-1.2). Pathologic observation suggested
T-lineage lymphoid malignancy. The immunohistochemistry
panel used to define the diagnosis was as follows: a panel of
monoclonal antibodies against CD 3, CD 4, CD 8, CD 20,
CD 30, CD 56, TIA-1, Granzyme B (all from DAKO,
Copenhagen, Denmark), and Ki-67(DAKO, Glostrup,
Denmark). Using ISH (in situ hybridization) technique,
Epstein-Barr virus(EBV)-encoded RNA (EBERs) was de-
tected. Paraffin sections were pretreated with xylene followed
by proteinase K (Merck, Darmstadt, Germany), treatment,
which was hybridized with fluorescein isothiocyanate-
conjugated EBV oligonucleotides (Novocastra, Newcastle,
U.K.) complementary to the mRNA portion of the EBER
genes. A confirmative diagnosis of punch biopsy was
PTCL, not otherwise specified (NOS) (Figure 1).
Tumor cells were immunonegative for EBERs and
Human T-cell leukemia virus type 1. The staging work-up
was performed according to the Ann Arbor stagingFigure 1 A punch biopsy of the tongue base showed a diffuse dense
staining of tumor cells. (B) The tumor cells showed a diffuse cytoplasmic im
for CD20, CD30, and CD56. The immunophenotype of tumor cells were mi
granule associated proteins TIA-1 and granzyme B. (D) The proliferation indclassification. A computed tomography (CT) scan of
the H&N and positive emission tomography (PET) were
evaluated. A bone-marrow (BM) biopsy was also per-
formed. H&N CT showed an ill-defined heterogeneous
enhancing soft tissue mass in the right tongue base, which
extended to the right pyriform sinus. There were slightly
enlarged enhancing lymph nodes in the right neck at level
II. F-18 FDG PET revealed a hypermetabolic lesion (SUV
max 8.18) in the right tongue base and lymph node (SUV
max 1.5) in the right neck level II (Figure 2). BM biopsy
showed a negative result for lymphomatous infiltration.
Lumbar puncture was not attempted in this patient.
According to the international prognostic index (IPI)
scoring system, the patient was categorized as the low
IPI group. Under the confirmed diagnosis of PTCL stage
IIA, IFRT began after 8 cycles of CHOP (cyclophospha-
mide, doxorubicin, vincristine, and prednisone) regimen
chemotherapy. Using VMAT providing better normal tis-
sue sparing than 3D-CRT, the total RT dose of 50.6 Gy
was delivered in 22 fractions for 4.5 weeks. After adminis-
tration of 34.5 Gy, the shrinking field technique was usedinfiltration of the lymphoid cells (x 400). (A) Immunohistochemical
munopositivity for CD3 (x400), but tumor cells were immunonegative
xed pattern for CD4 and CD8. (C) The tumor cells expressed cytotoxic
ex by Ki-67 immunostain expressed with a high level (about 80%).
Figure 2 F-18 FDG PET and CT scan findings. (A) Ill defined heterogeneous enhancing soft tissue mass lesion in the right tongue base and
enlarged lymph nodes in the right level II are observed on a plain contrast CT scan. (B) F-18 FDG PET reveals a hypermetabolic lesion (arrow) in
the right tongue base and lymph node in the right level II. (C) A follow-up CT scan reveals no evidence of mass lesion in the right tongue and
no significant lymph node in both necks after the treatment. (D) After the treatment, a 1 month follow-up PET scan shows disappearance of the
previous hypermetabolic lesion.
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(Figure 3). The patient was also assessed for salivary gland
toxicity using Radiation Therapy Oncology Group (RTOG)
late toxicity grading. Although the patient achieved
complete remission without any morbidity relating to
VMAT during the follow-up period, recurrence oc-
curred in the orbit (including right lower eyelid) at
3 months after the treatment (Figure 4). A diagnosis of
recurrence via excisional biopsy revealed PTCL, NOS.
After a diagnosis of recurrence, the patient received
RT with high energy electron on the right orbit (Figure 4).
Eight cycles of salvage chemotherapy with IMEP (ifosfa-
moide, methotrexate, etoposide, and prednisolone) regi-
men was followed by RT. The patient died of aggravation
of PTCL at 17 months after VMAT.
Discussion
The etiology of primary BOT lymphoma is little known,
although some cases of lymphomas have been reported
in association with the acquired immune deficiency syn-
drome (Delecluse et al. 1997). PTCLs is reported to be
distinct from cutaneous T- cell lymphoma and have poor
prognosis (Foss et al. 2011). According to the fourth edi-
tion of the World Health Organization Classification ofTumors of Hematopoietic and Lymphoid Tissues (Swerdlow
et al. 2008). PTCL, NOS is classified into the nodal lymph-
oma group in which, along with extranodal and leukemic
groups, most of aggressive T-cell lymphoma are included
(Campo et al. 2011).
Patients with PTCL had a very poor outcome com-
pared with patients with aggressive B-cell lymphoma.
The International T-cell Lymphoma Study showed that
the overall survival and failure-free survival with PTCL,
NOS at 10 to 15 years was 10% (Vose et al. 2008).
Suzzumiya et al. reported that in aggressive T-cell
lymphomas, patients with high IPI score had adverse
outcomes compared with patients with low IPI, similar
to diffuse large B-cell lymphoma. However, they showed
that even patients in the best IPI score group did not
have a favorable survival. In this study, the patient
showed a bad prognosis even with a low IPI score
(Suzumiya et al. 2009).
There have been many clinical and laboratory results,
which evaluate the molecular and immunohistochemical
prognostic factors in PTCL subtypes. Went et al. re-
ported that the proliferation-associated protein Ki-67
was prognostically relevant and a new predictive score
including age (>60 years), high LDH, poor performance
Figure 3 The patient received volumetric modulated arc therapy for parotid gland sparing with (A) dose prescription of 3,450 cGy in
15 fractions over 3 weeks plus (B) a local boost of 1,610 cGy to the primary site in 7 fractions over 1 week. The total RT dose was
delivered 50.6 Gy in 22 fractions over 4.5 weeks.
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the patient outcome (Went et al. 2006). In our study, the
patient's Ki-67 was expressed with a high level (about
80%). These results seem to also affect the poor out-
comes in this case. In this patient, diagnostic lumbar
puncture to rule out central nervous system involvement
(CNS) was not performed. In our institution, lumbar
puncture is performed if the physician suspects that
lymphoma has spread to the central nervous system or
bone marrow. In addition, lumbar puncture is performed
routinely for aggressive lymphomas (such as primary
CNS lymphoma), paranasal sinus, parameningeal, testicu-
lar involvement, and patients with lymphobastic lymph-
oma, Burkitt lymphoma, and blastic variants.
Although there was a poor outcome in our patient, we
identified the usefulness of VMAT. During the follow-up
period, the patient did not develop any morbidities relat-
ing to VMAT, including xerostomia. The patient did not
develop grade ≥1 xerostomia according to the RTOG
criteria. Xerostomia after RT for Waldeyer's NHL was
known to be a considerable morbidity and parotid-
sparing RT techniques was recommended to reduce
these complications (Chang et al. 2009). Traditional RT
technique for Waldeyer`s NHL is opposed lateral fields
to cover the primary tumor lesion and neck lymph
nodes. This RT field also includes the bilateral parotidglands. Therefore, most of patients treated with traditional
RT technique experience xerostomia which is permanent
toxicity and can alleviate the patient's quality of life. The
most well-known parotid sparing technique, intensity
modulated radiation therapy (IMRT), improves RT in-
duced xerostomia related quality of life compared to
traditional RT technique (Gupta et al. 2012; van Rij
et al. 2008). VMAT is the next version of IMRT and more
fast and efficient than IMRT (Verbakel et al. 2009).
Although there is no consensus on the question of
how to best treat primary BOT lymphoma, the recom-
mended treatment modality for patients with early stage
is combined therapy consisting of chemotherapy and RT
(You et al. 2004). T-cell lymphoma have traditionally
been treated much like the B-cell lymphomas, with a
combination chemotherapy regimen. Currently, there is
no standard first-line regimen for the treatment of PTCL
(Foss et al. 2011). The most common chemotherapeutic
regimen for the treatment of PTCL is the CHOP regi-
men (Savage 2011). According to the trend described
above, our patient also received CHOP regimen followed
by RT. For patients with recurrent PTCL, the optimal
therapeutic management is unclear, and data regarding
the outcome for relapsed patients is limited (Lunning
et al. 2013). The second-line combination regimens are
reported to be similar to those studied in relapsed
Figure 4 Compared to CT and PET scan 3 months ago. (A) Follow-up CT scan shows developed homogenous enhancing lesion surrounding
the right orbit and right lower eyelid, and (B) the hypermetabolic lesion in the right orbit were newly disappeared in the follow-up PET scan.
(C, D) The patient received RT with high energy electron to the right orbit.
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(ifosphamide, carboplatin, and etoposide), DHAP (dexa-
methasone, cytarabine, and cisplatin), and ESHAP (etopo-
side, methylprednisolone, cisplatin, and cytarabine). In
this study, eight cycles of salvage chemotherapy with
IMEP regimen was followed by RT. Because the recur-
rence was localized within the orbit at the time of diag-
nosis of the recurrence, the patient received RT before
salvage chemotherapy.
For improving the treatment outcome in primary and
relapsed PTCL patients, new therapeutic agents are cur-
rently used or in clinical trials. The agents showing ac-
tivity in PTCL are as follows: immunomodulatory agents
(brentuximab, alemtuzumab, and lenalidomide), antifo-
lates (pralatrexate), nucleoside analogs (gemcitabine),
histone deacetylase inhibitors (belinostat, vorinostat,
and romidepsin) (Petrich and Rosen 2013; Karlin and
Coiffier 2014; Foss et al. 2011).
Furthermore, the trials comparing autologous and allo-
genic hematopoietic cell transplantation in eligible pa-
tients were also initiated by the German High-Grade
Non-Hodgkin Lymphoma Study Group (Shustov 2013).
The results of these trials might help elucidate difficult
treatment decisions for relapsed PTCL. Some authorsbelieve that relapsed PTCL should be considered for
allogenic stem cell transplantation, if suitable (Lunning
and Horwitz 2013).
Conclusion
Primary PTCL of BOT is an extremely uncommon dis-
ease, and all reported studies include a small number of
patients. Although the patient in our report showed an
local control without any morbidity relating to RT dur-
ing the follow-up period, an early PTCL recurrence was
detected in the orbit after the treatment. These findings
support previous reports regarding PTCL adversely af-
fecting the patient outcomes and new therapeutic regi-
ments to best manage recurrent PTCL is warranted.
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